Evidence map›Paper›PMID 19885094›Full record

ArticleJournal of diabetes science and technology2007

Fiber-coupled fluorescence affinity sensor for 3-day in vivo glucose sensing.

Ralph Ballerstadt, Colton Evans, Ashok Gowda, Roger McNichols

Open access · bronzeAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A MEMS differential viscometric sensor for affinity glucose detection in continuous glucose monitoring.Journal of micromechanics and microengineering : structures, devices, and systems · 2013
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ralph BallerstadtBioTex, Inc., Houston, Texas 77054, USA. ralph@biotexmedical.com
Colton Evans
Ashok Gowda
Roger McNichols
Biotex (United States) · US

Funding

Fluorescence Sensor Probe for Glucose SensingR43DK067754 · NIDDK · BIOTEX, INC. · PI BALLERSTADT, RALPH · 2004 to 2004
$100k
NIDDK NIH HHS R43 DK067754
6 · The paper itself

Abstract

backgroundTo evaluate the feasibility of an implantable fiber-coupled fluorescence affinity sensor (FAS) for glucose monitoring in humans, we studied the acute and chronic in vivo performance in hairless rats and pigs.

methodsThe implantable fiber-coupled FAS was constructed by filling a dialysis chamber made of a regenerated cellulose membrane mounted to the distal tip of an optical fiber with fluorescent chemistry based on concanavalin A. Blood sugar changes in animals were induced by injections of insulin and dextrose. Determination of interstitial glucose concentrations in skin tissue was facilitated by measuring the fluorescence response of the FAS.

resultsThe acute in vivo response of the fiber-coupled FAS exhibited good correlation coefficients (>0.77) with blood sugar changes and minimal lag times (2-10 min) after 2 hours of sensor implantation. Equilibrium of the sensor signal with interstitial fluid was required less than 60 min after implantation. For both rats and pigs, chronic response of the FAS to blood sugar modulations measured during the third day of implantation successfully demonstrated proof-of-concept for short-term glucose monitoring. A slight decrease in sensitivity after 3 days in the small animal model was assumed to be caused by excessive mechanical forces on the implanted device because of high animal motility.

conclusionsOverall, the chronic in vivo performance of the FAS in two different animal models over 3 days was clinically acceptable and comparable to other continuous glucose monitoring platforms. The major benefit of the FAS is the absence of "autodestructive" side products and any device-related warm-up time after sensor reconnection.

Indexed as

affinityconcanavalin Adextrandiabetesfluorescenceglucose monitoringhollow fiber

Identifiers

PMID19885094
PMCPMC2769588
OpenAlexW1982025288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.